ImmuPharma plc (LON:IMM – Get Free Report) was down 6.7% during trading on Wednesday . The company traded as low as GBX 4.50 ($0.06) and last traded at GBX 4.67 ($0.06). Approximately 5,281,667 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 22,218,395 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Price Performance
The stock has a market capitalization of £18.17 million, a price-to-earnings ratio of -436.40 and a beta of 1.53. The firm has a 50 day simple moving average of GBX 2.28 and a 200-day simple moving average of GBX 1.89.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Alphabet Stock Dip: A Prime AI-Powered Buying Opportunity
- What is a Special Dividend?
- Costco: A Retail Powerhouse Defying Economic Challenges
- Consumer Staples Stocks, Explained
- 3 Stocks Under $10 That Could Turn Risk Into Reward
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
